+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Ramucirumab"

Cyramza (ramucirumab; Eli Lilly) Drug Overview 2019 - Product Thumbnail Image

Cyramza (ramucirumab; Eli Lilly) Drug Overview 2019

  • Drug Pipelines
  • September 2019
  • 65 Pages
  • Global
From
Loading Indicator

Ramucirumab is a monoclonal antibody used in the treatment of certain types of cancer. It is used in combination with other drugs to treat metastatic gastric cancer, metastatic non-small cell lung cancer, and metastatic colorectal cancer. It works by blocking the action of a protein called vascular endothelial growth factor (VEGF), which helps cancer cells grow and spread. Ramucirumab is approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Ramucirumab is a relatively new drug in the oncology market, but it has been gaining traction in recent years. It is used in combination with other drugs to treat a variety of cancers, and it has been shown to be effective in prolonging survival in some patients. It is also being studied in combination with other drugs for the treatment of other types of cancer. Some of the companies in the Ramucirumab market include Eli Lilly, AstraZeneca, Merck, and Pfizer. Show Less Read more